CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2

Context.— CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas. However, studies have shown that CDH17...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Archives of pathology & laboratory medicine (1976) Ročník 141; číslo 1; s. 144 - 150
Hlavní autoři:	Altree-Tacha, David, Tyrrell, Jillian, Haas, Thomas
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States College of American Pathologists 01.01.2017
Témata:	Adenocarcinoma Adenocarcinoma - diagnosis Adenocarcinoma - metabolism Biomarkers, Tumor - analysis Cadherins - analysis Care and treatment CDX2 Transcription Factor - analysis Diagnosis Fixatives Formaldehyde Genetic aspects Health aspects Humans Immunohistochemistry - methods Immunohistochemistry - statistics & numerical data Innovations Keratin-20 - analysis Membrane proteins Molecular diagnostic techniques Paraffin Embedding Sensitivity and Specificity Stomach cancer Stomach Neoplasms - diagnosis Stomach Neoplasms - metabolism Tissue Array Analysis - methods Tissue Array Analysis - statistics & numerical data Tissue Fixation
ISSN:	0003-9985, 1543-2165, 1543-2165
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Context.— CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas. However, studies have shown that CDH17 is a highly specific marker for gastrointestinal adenocarcinoma and may be important in clinical diagnosis. Objective.—To evaluate the sensitivity and specificity of CDH17, CK20, and CDX2 antibodies in neoplastic tissues, with emphasis on colon, stomach, and esophageal gastrointestinal lineage. Design.—Immunohistochemistry was performed with CDH17, CK20, and CDX2 antibodies on formalin-fixed, paraffin-embedded tissue microarrays from normal (n = 26) and neoplastic (n = 884) tissues. Results.—CDH17 immunostaining was positive in 97.3% (145 of 149) of colon adenocarcinomas, whereas CK20 and CDX2 stained positively in 88.6% (132 of 149) and 93.3% (139 of 149), respectively. In metastatic colon cancers, CDH17, CK20, and CDX2 positive staining was observed in 90.6% (29 of 32), 59.4% (19 of 32), and 81.3% (26 of 32) of cases, respectively. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. In esophageal adenocarcinomas, CDH17, CK20, and CDX2 stained 38.7% (12 of 31), 25.8% (8 of 31), and 29% (9 of 31) of specimens, respectively. Low or no expression was observed in other neoplastic tissues, except pancreatic cancers, where CDH17 displayed higher expression than CK20 and CDX2. Conclusions.—CDH17 is a specific and more sensitive marker in the gastrointestinal tract than CK20 and CDX2. CDH17 may be especially valuable when gastrointestinal tumors are suspected in cancers of unknown primary.
AbstractList	Context.— CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas. However, studies have shown that CDH17 is a highly specific marker for gastrointestinal adenocarcinoma and may be important in clinical diagnosis. Objective.—To evaluate the sensitivity and specificity of CDH17, CK20, and CDX2 antibodies in neoplastic tissues, with emphasis on colon, stomach, and esophageal gastrointestinal lineage. Design.—Immunohistochemistry was performed with CDH17, CK20, and CDX2 antibodies on formalin-fixed, paraffin-embedded tissue microarrays from normal (n = 26) and neoplastic (n = 884) tissues. Results.—CDH17 immunostaining was positive in 97.3% (145 of 149) of colon adenocarcinomas, whereas CK20 and CDX2 stained positively in 88.6% (132 of 149) and 93.3% (139 of 149), respectively. In metastatic colon cancers, CDH17, CK20, and CDX2 positive staining was observed in 90.6% (29 of 32), 59.4% (19 of 32), and 81.3% (26 of 32) of cases, respectively. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. In esophageal adenocarcinomas, CDH17, CK20, and CDX2 stained 38.7% (12 of 31), 25.8% (8 of 31), and 29% (9 of 31) of specimens, respectively. Low or no expression was observed in other neoplastic tissues, except pancreatic cancers, where CDH17 displayed higher expression than CK20 and CDX2. Conclusions.—CDH17 is a specific and more sensitive marker in the gastrointestinal tract than CK20 and CDX2. CDH17 may be especially valuable when gastrointestinal tumors are suspected in cancers of unknown primary. Context.--CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas. However, studies have shown that CDH17 is a highly specific marker for gastrointestinal adenocarcinoma and may be important in clinical diagnosis. Objective.--To evaluate the sensitivity and specificity of CDH17, CK20, and CDX2 antibodies in neoplastic tissues, with emphasis on colon, stomach, and esophageal gastrointestinal lineage. Design.--Immunohistochemistry was performed with CDH17, CK20, and CDX2 antibodies on formalin-fixed, paraffin-embedded tissue microarrays from normal (n = 26) and neoplastic (n = 884) tissues. Results.--CDH17 immunostaining was positive in 97.3% (145 of 149) of colon adenocarcinomas, whereas CK20 and CDX2 stained positively in 88.6% (132 of 149) and 93.3% (139 of 149), respectively. In metastatic colon cancers, CDH17, CK20, and CDX2 positive staining was observed in 90.6% (29 of 32), 59.4% (19 of 32), and 81.3% (26 of 32) of cases, respectively. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. In esophageal adenocarcinomas, CDH17, CK20, and CDX2 stained 38.7% (12 of 31), 25.8% (8 of 31), and 29% (9 of 31) of specimens, respectively. Low or no expression was observed in other neoplastic tissues, except pancreatic cancers, where CDH17 displayed higher expression than CK20 and CDX2. Conclusions.--CDH17 is a specific and more sensitive marker in the gastrointestinal tract than CK20 and CDX2. CDH17 may be especially valuable when gastrointestinal tumors are suspected in cancers of unknown primary. doi: 10.5858/arpa.2015-0404-OA CONTEXT-CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas. However, studies have shown that CDH17 is a highly specific marker for gastrointestinal adenocarcinoma and may be important in clinical diagnosis.OBJECTIVE-To evaluate the sensitivity and specificity of CDH17, CK20, and CDX2 antibodies in neoplastic tissues, with emphasis on colon, stomach, and esophageal gastrointestinal lineage.DESIGN-Immunohistochemistry was performed with CDH17, CK20, and CDX2 antibodies on formalin-fixed, paraffin-embedded tissue microarrays from normal (n = 26) and neoplastic (n = 884) tissues.RESULTS-CDH17 immunostaining was positive in 97.3% (145 of 149) of colon adenocarcinomas, whereas CK20 and CDX2 stained positively in 88.6% (132 of 149) and 93.3% (139 of 149), respectively. In metastatic colon cancers, CDH17, CK20, and CDX2 positive staining was observed in 90.6% (29 of 32), 59.4% (19 of 32), and 81.3% (26 of 32) of cases, respectively. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. In esophageal adenocarcinomas, CDH17, CK20, and CDX2 stained 38.7% (12 of 31), 25.8% (8 of 31), and 29% (9 of 31) of specimens, respectively. Low or no expression was observed in other neoplastic tissues, except pancreatic cancers, where CDH17 displayed higher expression than CK20 and CDX2.CONCLUSIONS-CDH17 is a specific and more sensitive marker in the gastrointestinal tract than CK20 and CDX2. CDH17 may be especially valuable when gastrointestinal tumors are suspected in cancers of unknown primary. doi: 10.5858/arpa.2015-0404-OA -CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas. However, studies have shown that CDH17 is a highly specific marker for gastrointestinal adenocarcinoma and may be important in clinical diagnosis. -To evaluate the sensitivity and specificity of CDH17, CK20, and CDX2 antibodies in neoplastic tissues, with emphasis on colon, stomach, and esophageal gastrointestinal lineage. -Immunohistochemistry was performed with CDH17, CK20, and CDX2 antibodies on formalin-fixed, paraffin-embedded tissue microarrays from normal (n = 26) and neoplastic (n = 884) tissues. -CDH17 immunostaining was positive in 97.3% (145 of 149) of colon adenocarcinomas, whereas CK20 and CDX2 stained positively in 88.6% (132 of 149) and 93.3% (139 of 149), respectively. In metastatic colon cancers, CDH17, CK20, and CDX2 positive staining was observed in 90.6% (29 of 32), 59.4% (19 of 32), and 81.3% (26 of 32) of cases, respectively. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. In esophageal adenocarcinomas, CDH17, CK20, and CDX2 stained 38.7% (12 of 31), 25.8% (8 of 31), and 29% (9 of 31) of specimens, respectively. Low or no expression was observed in other neoplastic tissues, except pancreatic cancers, where CDH17 displayed higher expression than CK20 and CDX2. -CDH17 is a specific and more sensitive marker in the gastrointestinal tract than CK20 and CDX2. CDH17 may be especially valuable when gastrointestinal tumors are suspected in cancers of unknown primary.
Audience	Professional Academic
Author	Tyrrell, Jillian Haas, Thomas Altree-Tacha, David
Author_xml	– sequence: 1 givenname: David surname: Altree-Tacha fullname: Altree-Tacha, David – sequence: 2 givenname: Jillian surname: Tyrrell fullname: Tyrrell, Jillian – sequence: 3 givenname: Thomas surname: Haas fullname: Haas, Thomas organization: From Chief Scientific Officer (Dr Altree-Tacha) and the Department of Research and Development (Dr Tyrrell), Biocare Medical, Concord, California; and the Department of Pathology, Mercy Health System, Janesville, Wisconsin (Dr Haas)
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28029907$$D View this record in MEDLINE/PubMed
BookMark	eNp1kl1rFDEUhoNU7Lb6A7yRgCDezHqSSebjcplqW2zdCyt4F7L56KbOJNtkRvDfm7Et2rKSi0PC876cnPMeoQMfvEHoNYElb3jzQcadXFIgvAAGrFivnqEF4awsKKn4AVoAQFm0bcMP0VFKN_naUkpeoEPaAG1bqBfoS3dyRmp8nrDElyEa_NX45Eb30-BLGX-YiG2I-FSmMTqFV9r4oGRUzodB4qut9Lj7TAFLr3F38p2-RM-t7JN5dV-P0bdPH6-6s-JifXrerS4KxWs2FgwqYMYybjUpNdOS1YaURBNb1ZpbpmjV0A1TCohsNrCxVdU2JdSqtMA1VeUxen_nu4vhdjJpFINLyvS99CZMSZCGMwKsJmVG3z5Bb8IUfe7uD0WBNRX9S13L3gjnbRijVLOpWHGSp1VxYJkq9lDXxpso-7wb6_LzI365h89Hm8GpvYJ3_wi2RvbjNoV-Gl3w6TH45v5X02YwWuyiG2T8JR42m4H6DlAxpBSNFcqNcvbJLbheEBBzhsScITFnSMwZEutVVpInygfz_2t-A-URwvw
CODEN	APLMAS
CitedBy_id	crossref_primary_10_1186_s40001_025_02761_7 crossref_primary_10_1007_s12094_017_1807_y crossref_primary_10_1007_s12149_019_01408_y crossref_primary_10_3390_ijms26146960 crossref_primary_10_1016_j_prp_2024_155175 crossref_primary_10_3892_etm_2025_12883 crossref_primary_10_1080_14737159_2023_2176223 crossref_primary_10_1097_PAP_0000000000000256 crossref_primary_10_1016_j_bbcan_2024_189228 crossref_primary_10_3389_fonc_2021_699401 crossref_primary_10_1097_PAS_0000000000001583 crossref_primary_10_1186_s12951_023_02133_5 crossref_primary_10_1007_s12029_020_00513_w crossref_primary_10_1038_s43018_022_00344_7 crossref_primary_10_1245_s10434_024_15570_9 crossref_primary_10_1016_j_anndiagpath_2019_151419 crossref_primary_10_1002_adfm_202209393 crossref_primary_10_1007_s00428_023_03583_w crossref_primary_10_1002_jso_26399 crossref_primary_10_3390_cancers13133194 crossref_primary_10_1002_cnr2_70069 crossref_primary_10_1097_MNM_0000000000001203 crossref_primary_10_3390_ijms20133373 crossref_primary_10_1016_j_ctarc_2020_100300 crossref_primary_10_1186_s12885_025_13810_z
Cites_doi	10.1007/s10350-007-9034-1 10.1309/AJCPKSHXI3XEHW1J 10.1186/1746-1596-7-9 10.1093/jjco/hyp150 10.1038/modpathol.2012.229 10.1016/j.humpath.2003.12.007 10.1038/modpathol.2008.107 10.1097/00000478-200303000-00003 10.5858/arpa.2013-0452-OA 10.1038/modpathol.3880175 10.1097/IGC.0b013e318261d89c 10.1053/hupa.2002.129422 10.1371/journal.pone.0056959 10.1158/1078-0432.CCR-05-0278 10.1016/j.prp.2010.12.005 10.1038/modpathol.3800698
ContentType	Journal Article
Copyright	COPYRIGHT 2017 College of American Pathologists Copyright College of American Pathologists Jan 2017
Copyright_xml	– notice: COPYRIGHT 2017 College of American Pathologists – notice: Copyright College of American Pathologists Jan 2017
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 4T- 4U- 7RV 7X7 7XB 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. KB0 LK8 M0S M1P M2P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8
DOI	10.5858/arpa.2015-0404-OA
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Docstoc University Readers Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database (via ProQuest SciTech Premium Collection) Biological Science Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) University Readers ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Docstoc ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1543-2165
EndPage	150
ExternalDocumentID	4289972411 A510296504 28029907 10_5858_arpa_2015_0404_OA
Genre	Journal Article General Information
GroupedDBID	--- -~X .55 04C 23N 2WC 36B 53G 5GY 5RE 6PF 7RV 7X7 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 AAQOH AAWTL AAYXX ABCQX ABDBF ABOCM ABUWG ACGFO ACGOD ACPRK ACUHS ADBBV ADOJX AENEX AFFHD AFKRA AFKWF AHMBA ALMA_UNASSIGNED_HOLDINGS AZQEC B0M BAIFH BAWUL BBNVY BBTPI BENPR BHPHI BKEYQ BKOMP BMSDO BPHCQ BVXVI CCPQU CITATION DIK DWQXO E3Z EAP EAS EBC EBD EBS ECF ECT ECV EHN EIHBH EJD EMB EMK EMOBN ENC EPL EPT ESX F5P FAC FAL FJD FJW FRP FYUFA GNUQQ GX1 HCIFZ HMCUK IAO IEA IHR IHW INH INR IOF ITC L7B LK8 M1P M2P M2Q M7P NAPCQ OK1 P2P PCD PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PV9 Q2X Q~Q RWL RXW RZL SV3 TAE TAF TR2 TUS TWZ UDS UKHRP W2D WH7 WQ9 X6Y X7M Y3D ~8M .GJ 1CY 3O- AAQQT AFFNX ALIPV C1A CGR CUY CVF ECM EIF EX3 J5H NPM WOW YQJ ZGI ZXP 3V. 4T- 4U- 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO
ID	FETCH-LOGICAL-c574t-40604ef45fd13d4da47e131d1f67d5f4c2682b4cc01a8b0bf6698307c3f05d2c3
IEDL.DBID	M2P
ISICitedReferencesCount	36
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000396375800021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0003-9985 1543-2165
IngestDate	Fri Sep 05 14:17:22 EDT 2025 Mon Oct 06 18:34:24 EDT 2025 Tue Nov 11 10:07:18 EST 2025 Sat Nov 29 11:49:45 EST 2025 Tue Nov 04 17:48:30 EST 2025 Thu May 22 21:22:19 EDT 2025 Thu Apr 03 06:58:15 EDT 2025 Tue Nov 18 21:25:24 EST 2025 Sat Nov 29 03:10:41 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c574t-40604ef45fd13d4da47e131d1f67d5f4c2682b4cc01a8b0bf6698307c3f05d2c3
Notes	SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2015-0404-OA
PMID	28029907
PQID	1854204862
PQPubID	42082
PageCount	7
ParticipantIDs	proquest_miscellaneous_1854104713 proquest_journals_1854204862 gale_infotracmisc_A510296504 gale_infotracgeneralonefile_A510296504 gale_infotracacademiconefile_A510296504 gale_healthsolutions_A510296504 pubmed_primary_28029907 crossref_citationtrail_10_5858_arpa_2015_0404_OA crossref_primary_10_5858_arpa_2015_0404_OA
PublicationCentury	2000
PublicationDate	2017-01-01
PublicationDateYYYYMMDD	2017-01-01
PublicationDate_xml	– month: 01 year: 2017 text: 2017-01-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Northfield
PublicationTitle	Archives of pathology & laboratory medicine (1976)
PublicationTitleAlternate	Arch Pathol Lab Med
PublicationYear	2017
Publisher	College of American Pathologists
Publisher_xml	– name: College of American Pathologists
References	Rao (2020081219462523000_i1543-2165-141-1-144-b13); 26 Werling (2020081219462523000_i1543-2165-141-1-144-b02) 2003; 27 Fan (2020081219462523000_i1543-2165-141-1-144-b09) 2005; 11 Chu (2020081219462523000_i1543-2165-141-1-144-b05) 2000; 13 Kim (2020081219462523000_i1543-2165-141-1-144-b10) 2004; 35 Lin (2020081219462523000_i1543-2165-141-1-144-b08) 2014; 138 Su (2020081219462523000_i1543-2165-141-1-144-b06) 2008; 21 Qiu (2020081219462523000_i1543-2165-141-1-144-b15) 2013; 8 Bayrak (2020081219462523000_i1543-2165-141-1-144-b03) 2012; 7 Panarelli (2020081219462523000_i1543-2165-141-1-144-b07) 2012; 138 Huang (2020081219462523000_i1543-2165-141-1-144-b16) 2012; 22 Shin (2020081219462523000_i1543-2165-141-1-144-b12) 2010; 40 Kwak (2020081219462523000_i1543-2165-141-1-144-b14) 2007; 50 Vang (2020081219462523000_i1543-2165-141-1-144-b11) 2006; 19 Park (2020081219462523000_i1543-2165-141-1-144-b01) 2002; 33 Bayrak (2020081219462523000_i1543-2165-141-1-144-b04) 2011; 207 28353385 - Arch Pathol Lab Med. 2017 Apr;141(4):484
References_xml	– volume: 50 start-page: 1873 issue: 11 year: 2007 ident: 2020081219462523000_i1543-2165-141-1-144-b14 article-title: The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer publication-title: Dis Colon Rectum doi: 10.1007/s10350-007-9034-1 – volume: 138 start-page: 211 issue: 2 year: 2012 ident: 2020081219462523000_i1543-2165-141-1-144-b07 article-title: Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2 publication-title: Am J Clin Pathol doi: 10.1309/AJCPKSHXI3XEHW1J – volume: 7 start-page: 9 year: 2012 ident: 2020081219462523000_i1543-2165-141-1-144-b03 article-title: The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody publication-title: Diagn Pathol doi: 10.1186/1746-1596-7-9 – volume: 40 start-page: 208 issue: 3 year: 2010 ident: 2020081219462523000_i1543-2165-141-1-144-b12 article-title: CK7, CK20, CDX2 and MUC2 immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyp150 – volume: 26 start-page: 725 issue: 5 ident: 2020081219462523000_i1543-2165-141-1-144-b13 article-title: Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers publication-title: Mod Pathol. 201; doi: 10.1038/modpathol.2012.229 – volume: 35 start-page: 576 issue: 5 year: 2004 ident: 2020081219462523000_i1543-2165-141-1-144-b10 article-title: Cytokeratin expression profile in gastric carcinomas publication-title: Hum Pathol doi: 10.1016/j.humpath.2003.12.007 – volume: 21 start-page: 1379 issue: 11 year: 2008 ident: 2020081219462523000_i1543-2165-141-1-144-b06 article-title: Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system publication-title: Mod Pathol doi: 10.1038/modpathol.2008.107 – volume: 27 start-page: 303 issue: 3 year: 2003 ident: 2020081219462523000_i1543-2165-141-1-144-b02 article-title: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas publication-title: Am J Surg Pathol doi: 10.1097/00000478-200303000-00003 – volume: 138 start-page: 1015 issue: 8 year: 2014 ident: 2020081219462523000_i1543-2165-141-1-144-b08 article-title: Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2013-0452-OA – volume: 13 start-page: 962 issue: 9 year: 2000 ident: 2020081219462523000_i1543-2165-141-1-144-b05 article-title: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases publication-title: Mod Pathol doi: 10.1038/modpathol.3880175 – volume: 22 start-page: 1170 issue: 7 year: 2012 ident: 2020081219462523000_i1543-2165-141-1-144-b16 article-title: Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e318261d89c – volume: 33 start-page: 1078 issue: 11 year: 2002 ident: 2020081219462523000_i1543-2165-141-1-144-b01 article-title: Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary publication-title: Hum Pathol doi: 10.1053/hupa.2002.129422 – volume: 8 start-page: e56959 issue: 3 year: 2013 ident: 2020081219462523000_i1543-2165-141-1-144-b15 article-title: Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling publication-title: PLoS One doi: 10.1371/journal.pone.0056959 – volume: 11 start-page: 6162 issue: 17 year: 2005 ident: 2020081219462523000_i1543-2165-141-1-144-b09 article-title: Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0278 – volume: 207 start-page: 156 issue: 3 year: 2011 ident: 2020081219462523000_i1543-2165-141-1-144-b04 article-title: Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas publication-title: Pathol Res Pract doi: 10.1016/j.prp.2010.12.005 – volume: 19 start-page: 1421 issue: 11 year: 2006 ident: 2020081219462523000_i1543-2165-141-1-144-b11 article-title: Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7 publication-title: Mod Pathol doi: 10.1038/modpathol.3800698 – reference: 28353385 - Arch Pathol Lab Med. 2017 Apr;141(4):484
SSID	ssj0009221
Score	2.3503587
Snippet	Context.— CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of... -CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of cytokeratin (CK)... Context.--CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of... doi: 10.5858/arpa.2015-0404-OA CONTEXT-CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of...
SourceID	proquest gale pubmed crossref
SourceType	Aggregation Database Index Database Enrichment Source
StartPage	144
SubjectTerms	Adenocarcinoma Adenocarcinoma - diagnosis Adenocarcinoma - metabolism Biomarkers, Tumor - analysis Cadherins - analysis Care and treatment CDX2 Transcription Factor - analysis Diagnosis Fixatives Formaldehyde Genetic aspects Health aspects Humans Immunohistochemistry - methods Immunohistochemistry - statistics & numerical data Innovations Keratin-20 - analysis Membrane proteins Molecular diagnostic techniques Paraffin Embedding Sensitivity and Specificity Stomach cancer Stomach Neoplasms - diagnosis Stomach Neoplasms - metabolism Tissue Array Analysis - methods Tissue Array Analysis - statistics & numerical data Tissue Fixation
Title	CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2
URI	https://www.ncbi.nlm.nih.gov/pubmed/28029907 https://www.proquest.com/docview/1854204862 https://www.proquest.com/docview/1854104713
Volume	141
WOSCitedRecordID	wos000396375800021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1543-2165 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009221 issn: 0003-9985 databaseCode: M7P dateStart: 19960301 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1543-2165 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009221 issn: 0003-9985 databaseCode: 7X7 dateStart: 19960301 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1543-2165 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009221 issn: 0003-9985 databaseCode: 7RV dateStart: 19960301 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1543-2165 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009221 issn: 0003-9985 databaseCode: BENPR dateStart: 19960301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1543-2165 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009221 issn: 0003-9985 databaseCode: 8C1 dateStart: 19960301 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1543-2165 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009221 issn: 0003-9985 databaseCode: M2P dateStart: 19960301 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoixAX3oVAWYyEQEKKGjtOnJxQSFuK0G5XpaC9WbbjtEiQLNktv5-ZJJsqFeqFy1w8TizP-PP49Q0hb-LAFKzksW-iJMatG3ysDEKHSD5n0zJMbJtsQs5myWKRzvsNt1V_rXKDiS1QF7XFPfJ9mFcEkszG_MPyt49Zo_B0tU-hsUV2ILJheKVryudXpLucDxnzYFkRdaeaECAn-7pZIusQi3zwYuGfZKN56To6X4s527nn6P7_tvoBuddHnTTr3OQhueWqR-TOtD9Xf0xm-cExk_Tzimo6rRtHv-K9dkRCio95XEMhtqWfNCb5sDQDrIIpsIG69S9Nzy50RfMvPKC6Kmh-sOBPyLejw7P82O8zLfg2kmINi8g4EK4UUVmwsBCFFtKxkIEVY1lEpbA8TrgR1gZMJyYwZRynCaCDDcsgKrgNd8l2VVfuGaGxkaEr0igCKBBGpkaIUEbOMmG4kTr1SLDpZ2V7GnLMhvFTwXIETaPQNApNo9A06iTzyPuhyrLj4LhJ-RUaT3XPSIfxqzIAH55CPCo88q7VwBEMf7a6f4gA7UcurJHm25HmeccE_i_FvZEiDFE7Lt54h-ohYqWuXMMjr4dirInX3ipXX3Y6yKXBQo887Txw6AGeBBhKyOc3f_wFucsxEml3jfbI9rq5dC_Jbftn_WPVTMiWPP2OciFbmYBMcjYhOx8PZ_PTSTueUMr5X-FRHMM
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgigX3g9DoYvEQ0Kyaq_XrwNCVkJJlCatRJByW9brdUECOzgpiD_Fb2TGryoV6q0HLrl41vHj229m1zPfALwInDRzcx7YqR8FtHVDxcr4ozwSn9Nx7kW6bjYRzmbRYhEfb8GfrhaG0io7TqyJOis17ZHvo18RJDIb8HfLHzZ1jaKvq10LjQYWE_P7Fy7ZVm_HQ3y_Lzk_eD8fjOy2q4Ct_VCsccEUOMLkws8z18tEpkRoXM_FKw7CzM-F5kHEU6G146ooddI8COIIZ4L2csfPuPbwvFfgqiBlMUoV5MdnIr-c9x36cBnjN19RMSCP9lW1JJUj17dx1gj7KNnwg-e9wbkYt_Z1B7f-t6d0G262UTVLmmlwB7ZMcReuT9u8gXswGwxHbsjGK6bYtKwM-0h5-8T0jIqVTMUwdmcfFDUx0SxBLkYXX-HY8rti8y-qYIMJd5gqMjYYLvh9-HQpd_MAtouyMI-ABWnomSz2faQ6kYZxKoQX-ka7IuVpqGILnO69St3KrFO3j28Sl1sEBUlQkAQFSVCQR4kFb_ohy0Zj5CLjPQKLbMpke36SCZIrjzHeFha8ri2IofCftWoLLfD6Setrw_LVhuVJo3T-L8PdDUOkIL15uEOjbClwJc-gaMHz_jCNpLS-wpSnjQ1phbieBQ8bxPdPgEcOhUrh44tPvgc7o_n0UB6OZ5MncINT1FXvkO3C9ro6NU_hmv65_rqqntVzlcHny4b9X5ojcwg
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFFVceD8ChS4SDwnJir1ee-0DQiFpaBSaRtBKuS3r9RqQwAlOCuKv8euY8SOVK9RbD1xy8azjx7ffzK5nvgF4FrpJ6mU8dJIgCmnrhoqV8Uf7JD5n4syPTNlsQk6n0Xwez7bgT1MLQ2mVDSeWRJ0uDO2R99CvCBKZDXkvq9MiZsPRm-UPhzpI0ZfWpp1GBZGJ_f0Ll2-r1-MhvuvnnI_2jwcHTt1hwDGBFGtcPIWusJkIstTzU5FqIa3ne3j1oUyDTBgeRjwRxriejhI3ycIwjnBWGD9zg5QbH897BbYlBhmiA9tv96ezD2eSv5xv-vXhoiaovqlieB71dLEkzSMvcHAOCeeo3_KK533DuYi39HyjG__zM7sJ1-t4m_WrCXILtmx-G3YO64yCOzAdDA88ycYrptnhorDsI2X0kw9gVMZkC4ZRPXunqb2JYX1kaXT-BY5dfNfs-IvO2WDCXabzlA2Gc34XTi7lbu5BJ1_k9gGwMJG-TeMgQBIUiYwTIXwZWOOJhCdSx11wm3esTC3ATn1AvilciBEsFMFCESwUwUId9bvwajNkWamPXGS8R8BRVQHthrlUH2mXxxiJiy68LC2Iu_Cfja5LMPD6SQWsZfmiZfm50kD_l-FuyxDJybQPN8hUNTmu1Bksu_B0c5hGUsJfbhenlQ2piHh-F-5X6N88AR65FETJhxeffA92EO3q_Xg6eQTXOIVj5dbZLnTWxal9DFfNz_XXVfGknrgMPl027v8CHV99Ig
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CDH17+Is+a+More+Sensitive+Marker+for+Gastric+Adenocarcinoma+Than+CK20+and+CDX2&rft.jtitle=Archives+of+pathology+%26+laboratory+medicine+%281976%29&rft.au=Altree-Tacha%2C+David&rft.au=Tyrrell%2C+Jillian&rft.au=Haas%2C+Thomas&rft.date=2017-01-01&rft.eissn=1543-2165&rft.volume=141&rft.issue=1&rft.spage=144&rft.epage=150&rft_id=info:doi/10.5858%2Farpa.2015-0404-OA&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-9985&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-9985&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-9985&client=summon